Gelteq Ltd
GELS Nasdaq· Pharmaceutical Preparations
Last close · Nov 13, 2026
$0.38
Latest fiscal year · FY25 results fiscal year ended Jun 30, 2025 · vs FY24
| Line | FY24 | FY25 | Change (y/y) |
|---|---|---|---|
| Revenue | — | $0.1M | — |
| Net income | −$2.3M | −$4.3M | — |
| Diluted EPS | −$0.29 | −$0.47 | — |
| Operating margin | — | −3,318.0% | — |
| Free cash flow | −$0.7M | −$3.6M | — |
Key numbers, fiscal 2025
Market cap
$3.5M
P/E
—
Revenue
$0.1M
Net income
−$4.3M
Free cash flow
−$3.6M
Operating margin
−3,318.0%
Gelteq Ltd in 30 seconds fiscal 2025
Are shareholders being diluted?
+14.2%
A lot. The share count rose 14.2% last year, so each share owns noticeably less.
Does it make a profit?
$0.4M R&D
Not yet: it has no meaningful sales. It spent $0.4M on research and development, 11% of its operating costs.
How long would its cash last?
0.1 yrs
Not long. It burns $3.6M a year and holds $0.2M, under a year at that pace, so it may need new money soon.
Is debt under control?
$2.5M
Risky. It owes more than it holds in cash and has no operating profit to repay it.
How healthy are the accounts?
2 / 7
It passes 2 of 7 health tests, but most of them need sales, so the score says little before revenue starts.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Gelteq Ltd does
Gelteq develops edible gel products that carry medicines, nutrients and other ingredients for people and animals. Its white-label products are sold by other companies under their own brands. The product range covers pets, sports nutrition, pharmaceuticals, over-the-counter products and nutraceuticals, such as vitamins and supplements. The gels can combine multiple ingredients in one measured dose and are designed to mask unpleasant tastes and make products easier to swallow. Gelteq also licenses its gel technology to companies that develop, manufacture and sell products in their own markets. Gelteq focuses on licensing its technology and making existing products under license. Its products serve pet care, sports, pharmaceutical, over-the-counter and nutraceutical markets. Sports gels contain electrolytes and carbohydrates; pet products address needs such as joint health, coat quality and digestion.
- Fiscal year ends
- June 30, 2025
- Latest annual report
- 20-F · Nov 17, 2025
- Legal name
- Gelteq Ltd
- CIK
- 0001920092
Gelteq Ltd · GELS · stoqly.net
Results and finances
The last 3 fiscal years. Amounts in USD. Compiled by stoqly.net.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Revenue | $0.1M | — | $0.1M |
| Gross margin | — | — | 30.3% |
| Operating margin | −3,884.9% | — | −3,318.0% |
| Net income | −$2.4M | −$2.3M | −$4.3M |
| Net margin | −4,390.9% | — | −4,012.2% |
| Diluted EPS | −$0.30 | −$0.29 | −$0.47 |
| Cash | |||
| Cash from operations | −$1.2M | −$0.7M | −$3.6M |
| Capital expenditure | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$1.2M | −$0.7M | −$3.6M |
| FCF margin | −2,260.3% | — | −3,335.6% |
| Share count change | — | 2.2% | 14.2% |
| Debt and strength | |||
| Cash and short-term investments | $0.3M | $0.0M | $0.2M |
| Debt incl. finance leases | $1.6M | $2.6M | $2.8M |
| Shareholders' equity | $12.4M | $10.1M | $10.3M |
| Current ratio | 0.7x | 0.1x | 0.3x |
| Interest coverage | −7.7x | −4.9x | −2.9x |
| Returns and quality | |||
| Return on capital | −12.0% | −12.1% | −21.9% |
| Return on equity | −19.1% | −20.7% | −42.2% |
| Piotroski F-score | — | 1 | 2 |
Insider trades 12 months
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Gelteq Ltd · GELS · stoqly.net
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Compiled and analysed by stoqly.net from SEC EDGAR XBRL filings (CIK 0001920092). Latest version: stoqly.net/companies/gels. Data updated November 9, 2026. Filed in AUD under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only — not investment advice. Check the original filings before relying on any figure.